All published articles of this journal are available on ScienceDirect.
Efalizumab in Psoriasis: Our Experience with 11 Patients
, 1
S. Diez-Moreno1
A. Molares1
A. Guerra-Tapia2
Authors Info & Affiliations
Abstract
This is an observational, longitudinal and retrospective study of a group of patients with moderate to severe plaque psoriasis whom had been treated with efaluzimab (1mg/Kg/week) for up to 20 weeks. Nevertheless, first dose of 0.7 mg/kg was given. The efficacy of the drug was evaluated by measuring the psoriasis area and severity index (PASI), the body surface area (BSA) and index of the quality of life (DLQI).
A statically significant improvement was observed in the PASI, BSA and DLQI after 4, 12 and 20 weeks of therapy.
After 20 weeks of treatment, the PASI 75 and 90 values were 100% and 97% respectively. When it comes to safety, efaluzimab was well tolerated and no remarkable side effects were recorded.
